Breaking News

Charles River, Curigin Partner to Produce Oncolytic RNAi Gene Therapy

Adenovirus production underpins preclinical trials targeting genes responsible for tumor growth.

Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing oncolytic ribonucleic acid interference (RNAi) gene therapies, are collaborating for adenoviral vector production. The gene therapy developer will leverage Charles River’s expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials. Curigin develops anticancer gene therapy products that utilize innovative genetically e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters